NCT06080165 2024-07-10
Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations
Stanford University
Phase 1/2 Withdrawn
Clinical Trials
12 trialsNCT00995059 2023-01-05
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Withdrawn
NCT01383668 2020-04-01
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
Mayo Clinic
Phase 1 Withdrawn
NCT03298958 2019-06-12
Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 3 Withdrawn
NCT03531281 2018-12-07
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Phase 1 Withdrawn
NCT02833506 2018-05-01
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT02126527 2016-08-26
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer
Mayo Clinic
Phase 1 Withdrawn
NCT01843998 2015-06-04
Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)
Medical College of Wisconsin
Phase 2 Withdrawn
NCT00002790 2015-03-06
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT00922129 2014-01-14
Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer
St. Joseph's Healthcare Hamilton
Phase 2/3 Withdrawn
NCT00957320 2013-12-03
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
Emory University
Phase 1 Withdrawn
NCT00098462 2012-10-04
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Withdrawn